Oric Pharmaceuticals



ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, M...

Matt Panuwat
Chief Business Officer
Christian V. Kuhlen
General Counsel
Dominic Piscitelli
Edna Chow Maneval
Senior Vice President, Clinical Development
Lori Friedman
Chief Scientific Officer
Pratik Multani
Chief Medical Officer

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.